Psychiatr. praxi. 2024;25(2):93-98 | DOI: 10.36290/psy.2024.015

ADHD in the spectrum of neurodevelopmental disorders: a case report of a combined deficit with comorbidities

MUDr. Hedvika Ernsten
Psychiatrické oddělení, Oblastní nemocnice Jičín

ADHD, as well as Asperger syndrome belong to the spectrum of neurodevelopmental disorders. Like each of them, it is defined among others by impaired growth and maturation of neurons leading to structural and functional abnormalities of the central nervous system. Attempts to a more systematic definition of their biomarkers are related to the effort to find a connection with the functional characteristics of this group of disorders. The progress of brain imaging methods offered by magnetic resonance has evolved from mere volumetry to determination of the structural abnormalities, herein focused at the white matter. As in all neurodevelopmental disorders overlapping areas exist in findings of white matter structure and in genomic findings, as well as an existing parallel in overlap of clinical manifestations. All neurodevelopmental disorders in general share a cognitive impairment the profile of which being characteristic for a particular diagnostic unit to some extent. However, its form in each individual patient is at the same time unique, being mostly composed of several types of deficits. The differentiation of individual aspects of cognition can be found in a detailed neurocognitive examination. The case report describing a 33-year-old patient thus offers a view of a neurodevelopmental continuum, not being strictly separated in diagnostic units. In each patient, instead of being fixed to diagnostic units it is advisable to focus on individual symptoms where we expect the possible benefit of pharmacotherapy. In case of a multiple deficit with comorbidities, we cannot avoid polypharmacotherapy, though as considerate as possible.

Keywords: neurodevelopmental disorders, ADHD, Asperger syndrome, cognitive impairment, executive functions impairment, Difuse Tensor Imaging, fraction anisotropy.

Accepted: May 29, 2024; Published: June 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ernsten H. ADHD in the spectrum of neurodevelopmental disorders: a case report of a combined deficit with comorbidities. Psychiatr. praxi. 2024;25(2):93-98. doi: 10.36290/psy.2024.015.
Download citation

References

  1. Song P, Zha M, Yang Q. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021 Feb 11;11:04009. doi: 10.7189/jogh.11.04009. PMID: 33692893; PMCID: PMC7916320. Go to original source... Go to PubMed...
  2. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-462. doi: 10.1016/S0140-6736(19)33004-1. Epub 2020 Jan 23. PMID: 31982036; PMCID: PMC7880081. Go to original source... Go to PubMed...
  3. Yadav SK, Bhat AA, Hashem S, et al. Genetic variations influence brain changes in patients with attention-deficit hyperactivity disorder. Transl Psychiatry. 2021 Jun 5;11(1):349. doi: 10.1038/s41398-021-01473-w. PMID: 34091591; PMCID: PMC8179928. Go to original source... Go to PubMed...
  4. González-Peñas J, Costas JC, García-Alcón A, et al. Psychiatric comorbidities in Asperger syndrome are related with polygenic overlap and differ from other Autism subtypes. Transl Psychiatry. 2020;10(1):258. Go to original source... Go to PubMed...
  5. Lau-Zhu A, Fritz A, McLoughlin G. Overlaps and distinctions between attention deficit/hyperactivity disorder and autism spectrum disorder in young adulthood: Systematic review and guiding framework for EEG-imaging research. Neurosci Biobehav Rev. 2019 Jan;96:93-115. doi: 10.1016/j.neubiorev.2018. 10. 009. Epub 2018 Oct 24. PMID: 30367918; PMCID: PMC6331660. Go to original source...
  6. Hosseini SA, Molla M. Asperger Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan. PMID: 32491480.
  7. Faridi F, Khosrowabadi R. Behavioral, Cognitive and Neural Markers of Asperger Syndrome. Basic Clin Neurosci. 2017 Sep-Oct;8(5):349-359. doi: 10.18869/nirp.bcn.8. 5. 349. PMID: 29167722; PMCID: PMC5691167. Go to original source...
  8. van Duin EDA, Zinkstok J, van Amelsvoort T, et al. White Matter Brain Structure in Asperger's Syndrome. 2014. doi:10.1007/978-1-4614-4788-7_115. Go to original source...
  9. Roine U, Roine T, Salmi J, et al. Increased coherence of white matter fiber tract organization in adults with Asperger syndrome: a diffusion tensor imaging study. Autism Res. 2013;6(6):642-650. Go to original source... Go to PubMed...
  10. Knott R, Johnson BP, Tiego J, et al. The Monash Autism-ADHD genetics and neurodevelopment (MAGNET) project design and methodologies: a dimensional approach to understanding neurobiological and genetic aetiology. Mol Autism. 2021 Aug 5;12(1):55. doi: 10.1186/s13229-021-00457-3. PMID: 34353377; PMCID: PMC8340366. Go to original source... Go to PubMed...
  11. van der Meer JM, Oerlemans AM, van Steijn DJ, et al. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry. 2012 Nov;51(11):1160-1172.e3. doi: 10.1016/j.jaac.2012. 08. 024. Epub 2012 Sep 30. PMID: 23101742. Go to original source...
  12. Bouziane C, Caan MWA, Tamminga HGH, et al. ADHD and maturation of brain white matter: A DTI study in medication naive children and adults. Neuroimage Clin. 2017;17:53-59. Go to original source... Go to PubMed...
  13. Udvardi PT, Föhr KJ, Henes C, et al. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain - an in vivo study. Drug Des Devel Ther. 2013;7:1433-1446. https://doi.org/10.2147/DDDT.S50448 Go to original source... Go to PubMed...
  14. Pittenger C. Pharmacotherapeutic Strategies and New Targets in OCD. Curr Top Behav Neurosci. 2021;49:331-384. doi: 10.1007/7854_2020_204. PMID: 33751503; PMCID: PMC8634155. Go to original source... Go to PubMed...
  15. MacDonald L, Sadek J. Management Strategies for Borderline Personality Disorder and Bipolar Disorder Comorbidities in Adults with ADHD: A Narrative Review. Brain Sci. 2023 Oct 26;13(11):1517. doi: 10.3390/brainsci13111517. PMID: 38002478; PMCID: PMC10669289. Go to original source... Go to PubMed...
  16. Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. doi: 10.1089/cap.2015.0137. Epub 2016 Feb 9. PMID: 26859445; PMCID: PMC4876529. Go to original source... Go to PubMed...
  17. Ding YS, Naganawa M, Gallezot JD, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage. 2014 Feb 1;86:164-71. doi: 10.1016/j.neuroimage.2013. 08. 001. Epub 2013 Aug 9. PMID: 23933039. Go to original source...
  18. Canu D, Ioannou C, Müller K, et al. Evidence towards a continuum of impairment across neurodevelopmental disorders from basic ocular-motor tasks. Sci Rep. 2022;12(1):16521. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.